Recent Ozempic, Victoza data ‘promising’ for diabetic kidney disease
Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk talks exclusively to PharmaTimes.
Read Moreby Anna Smith | Jun 25, 2019 | News | 0
Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk talks exclusively to PharmaTimes.
Read Moreby Anna Smith | Apr 26, 2019 | News | 0
Patients treated with oral semaglutide demonstrated greater HbA1c reductions and weight loss.
Read Moreby Anna Smith | Mar 14, 2019 | News | 0
Novo Nordisk presents ‘Ozempic’ interface at eyeforpharma conference in Barcelona.
Read Moreby Anna Smith | Jan 23, 2019 | News | 0
Novo Nordisk has announced that Ozempic, a new once-weekly GLP-1 (human glucagon-like peptide-1) analogue injection for the treatment of type II diabetes, is now available in the UK.
Read Moreby Selina McKee | Jun 25, 2018 | News | 0
Novo Nordisk has announced new data showing that its once-weekly glucagon-like peptide 1 (GLP-1) receptor agonist Ozempic provided greater weight reductions than Eli Lilly’s rival drug Trulicity in adults with type II diabetes.
Read Moreby Selina McKee | May 30, 2018 | News | 0
Novo Nordisk has announced headline data from the PIONEER 2 trial showing that oral semaglutide was better at improving HbA1c levels in patients with type II diabetes than Lilly’s and Boehringer Ingelheim’s Jardiance.
Read Moreby Selina McKee | Feb 12, 2018 | News | 0
European regulators have issued a green light for Novo Nordisk’s once-weekly diabetes therapy Ozempic.
Read Moreby Selina McKee | Dec 6, 2017 | News | 0
Novo Nordisk has garnered its first global approval for its once-weekly diabetes therapy Ozempic in the US.
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
